Glucagon vs Dasiglucagon
How they differ
- FDA status. Glucagon: FDA-approved as Gvoke, Baqsimi and other glucagon products.1,2,3,4 Dasiglucagon: FDA-approved as Zegalogue for severe low blood sugar; discontinued.5,6
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Glucagon | Dasiglucagon |
|---|---|---|
| What it is | A peptide hormone. The label states that glucagon raises blood sugar by activating glucagon receptors in the liver, which releases stored glucose.1 | A synthetic glucagon analogue of 29 amino acids that activates glucagon receptors in the liver, according to the Zegalogue label.6 |
| FDA status | FDA-approved FDA-approved as Gvoke, Baqsimi and other glucagon products1,2,3,4 FDA-approved. Drugs@FDA lists the first glucagon application with an approval date of November 14, 1960, and Gvoke with an approval date of September 10, 2019. The cited label has no boxed warning.1,2,4 | FDA-approved FDA-approved as Zegalogue for severe low blood sugar; discontinued5,6 FDA-approved, but discontinued. Drugs@FDA lists Zegalogue, NDA 214231, with an original approval date of March 22, 2021, and lists both of its products as discontinued.5 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 | Not among the six peptides the policy lists.7 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Dasiglucagon is not among them.7,8 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not listed. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list dasiglucagon.9 |
| Kinds of studies cited | Smaller controlled human trials
| Smaller controlled human trials
|
| Records collected | 31 ClinicalTrials.gov records and 255 PubMed records collected | 16 ClinicalTrials.gov records and 2 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA012122 · original submission status AP · 1960-11-14 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA210134 · original submission status AP · 2019-07-24 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA212097 · original submission status AP · 2019-09-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 6ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026